Under construction – not a live service
Sign in
Taking people in NetherlandsNo phase

Records outcomes of laser treatment for prostate cancer through the body's outer skin

Collects past records of men treated with transperineal laser ablation for prostate cancer.

Plain-language title generated from the registry record
Registry title: Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry

Key facts

Where
Amsterdam, NetherlandsSee the site

Where in Netherlands

  • Amsterdam University Medical CentersAmsterdam, NetherlandsTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial code
NCT05163197
Record updated
20 December 2021
Original description
Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes.Read full original descriptionShow less

Transperineal Laser Ablation Treatment for Prostate Cancer Registry: a Retrospective and Multicenter Evaluation

Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes.

Objective: To assess safety and feasibility of TPLA for PCa, to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort.

Study design: This is an international, retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa.

Study population: Male patients treated with TPLA for PCa. Main study parameters/endpoints: The primary endpoint of this registry is oncological outcomes of TPLA for PCa. Secondary endpoints are safety, feasibility and functional outcomes of TPLA for PCa.

Inclusion: Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed.

Exclusion: Age < 18 years.

ClinicalTrials.gov NCT05163197